STOCK TITAN

OrthoPediatrics (KIDS) 10-Q Filings

KIDS NASDAQ

Here are the 10-Q quarterly reports from OrthoPediatrics Corp. (KIDS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow KIDS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KIDS filings page.

Rhea-AI Summary

OrthoPediatrics Corp. (KIDS) reported third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier; nine-month revenue was $202.5 million, up 16% from $174.7 million. Management attributed growth primarily to global trauma and deformity products and specialty bracing. Gross margin was 74% in the quarter, unchanged year over year, and 74% for nine months, versus 73% in 2025. Net loss was $5.9 million for the quarter and $23.8 million for nine months, compared with $11.8 million and $29.5 million, respectively.

For the nine months ended September 30, 2026, net cash provided by operating activities was $2.1 million, compared with $15.2 million used in the prior-year period. Cash and cash equivalents, restricted cash and short-term investments totaled $44.9 million at September 30, 2026, while accumulated deficit was $299.0 million. Management believes available liquidity and expected operating cash flows are sufficient to maintain current and essential planned operations for more than the next twelve months.

A March 2026 amendment established a delayed draw term loan facility of not more than $20.0 million, subject to conditions, that may be drawn until June 30, 2027, in minimum $10.0 million increments. No amounts had been drawn as of September 30, 2026; loans are interest-only until August 5, 2029.

Rhea-AI Summary

OrthoPediatrics Corp. reported Q2 2026 net revenue of $70.5 million, up 15% from $61.1 million, with first‑half revenue rising 14% to $129.9 million. Growth was led by trauma and deformity products, where Q2 sales increased 26% to $52.6 million, while scoliosis Q2 revenue declined 9% to $16.9 million. Gross margin improved to 74% from 72% for both the quarter and year‑to‑date.

Q2 operating loss narrowed to $4.1 million from $10.7 million, but higher interest expense turned prior‑year other income into expense, leaving Q2 net loss essentially flat at $7.2 million (EPS $(0.30)). First‑half net loss was $17.9 million, or $(0.75) per share. At June 30, 2026, cash, restricted cash and short‑term investments totaled $47.9 million against total debt of $105.8 million, including a $51.0 million term loan and $50.0 million of 4.75% convertible notes due 2030. Net cash used in operating activities improved to $2.4 million from $14.6 million a year earlier. Management states that existing cash, expected cash flows and an undrawn $20.0 million delayed draw term loan under the Braidwell amendment are expected to support operations for more than 12 months.

Rhea-AI Summary

OrthoPediatrics Corp. reported first-quarter 2026 net revenue of $59.4 million, up 13% from $52.4 million a year earlier, driven by growth in trauma and deformity, scoliosis and specialty bracing across U.S. and international markets. Gross margin remained strong at 73%.

The company posted a net loss of $10.7 million, similar to the prior-year loss of $10.7 million, with loss per share of $0.45. Operating cash outflow improved to $3.3 million, and cash, restricted cash and short-term investments totaled about $50.9 million. Total debt was $106.7 million, including term loans and a 4.75% convertible note, and OrthoPediatrics added a new $20 million delayed draw term loan facility to expand future liquidity while continuing clinic acquisitions that increased goodwill to $115.2 million.

Rhea-AI Summary

OrthoPediatrics Corp. reported Q3 2025 results. Net revenue rose to $61,250 thousand from $54,573 thousand, with gross profit of $45,274 thousand. Operating expenses included intangible asset impairment of $2,268 thousand and restructuring of $2,294 thousand, resulting in an operating loss of $9,428 thousand versus $5,566 thousand a year ago. Net loss was $11,773 thousand, or $0.50 per share.

For the nine months, revenue reached $174,743 thousand versus $152,060 thousand, while net loss was $29,545 thousand. Cash was $16,826 thousand and short‑term investments were $40,902 thousand as of September 30, 2025. The company had a term loan of $51,000 thousand and a $50,000 thousand convertible note outstanding. It drew $25,000 thousand from its delayed‑draw term loan on June 27, 2025. Net cash used in operating activities was $15,199 thousand year‑to‑date.

U.S. sales were $48,718 thousand and international sales were $12,532 thousand in Q3. Shares outstanding were 25,077,330 as of October 28, 2025.